Category: Health Services, Science & Nature, Fitness

Tags: Upadacitinib in India, Rinvoq in India, JAK Inhibitor, rheumatoid arthritis, Inflammatory Diseases, Atopic Dermatitis, Ulcerative Colitis

Upadacitinib (Rinvoq) is an oral Janus kinase (JAK) inhibitor indicated for the treatment of several immune-mediated inflammatory disorders, including rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn's disease, ankylosing spondylitis, and other approved conditions in appropriate patients. It is available as extended-release tablets (15 mg, 30 mg, and 45 mg) and an oral solution (1 mg/mL). The recommended dosage varies according to the specific indication, disease severity, and treatment phase; patients should follow the prescribed dosing regimen outlined in the approved prescribing information.